secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001193125-25-283887
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA
--------------------------------------------------------------------------------

- Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.
- Ziihera + tislelizumab + chemo showed statistically significant OS and PFS improvements vs control.
- Benefit observed in both PD-L1 positive and negative subgroups; improvements in ORR and DoR.
- Company plans to submit sBLA in first half of 2026; data to be presented at medical meeting Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/0001193125-25-283887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer